An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

被引：0

作者：

Saiag, P. ^{[1
]}

Robert, C. ^{[2
]}

Grob, J. J. ^{[3
,4
]}

Mortier, L. ^{[5
]}

Dereure, O. ^{[6
]}

Lebbe, C. ^{[7
]}

Mansard, S. ^{[8
]}

Grange, F. ^{[9
]}

Neidhardt, E-M. ^{[10
]}

Lesimple, T. ^{[11
]}

Machet, L. ^{[12
,13
]}

Bedane, C. ^{[14
]}

Jeudy, G. ^{[15
]}

Aubin, F. ^{[16
]}

Dreno, B. ^{[17
]}

Szenik, A. ^{[18
]}

Denden, A. ^{[18
]}

Dutriaux, C. ^{[19
]}

机构：

[1] Ambroise Pare Hosp, AP HP, Dept Dermatol, Boulogne, France

[2] Inst Gustave Roussy, Dept Dermatol, Villejuif, France

[3] Aix Marseille Univ, Dept Dermatol, Marseille, France

[4] Univ Hosp Timone, APHM, Marseille, France

[5] Hop Claude Huriez, Dept Dermatol, Lille, France

[6] CHU Montpellier, Dept Dermatol, Montpellier, France

[7] Hop St Louis, Dept Dermatol Oncol, Paris, France

[8] CHU Estaing, Dept Dermatol, Clermont Ferrand, France

[9] Hosp Robert Debre, CHU Reims, Dept Dermatol, Reims, France

[10] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[11] Eugene Marquis Ctr, Dept Med Oncol, Rennes, France

[12] CHRU Tours, Dept Dermatol, Tours, France

[13] Univ Francois Rabelais Tours, Tours, France

[14] Hop Dupuytren, CHU Limoges, Dept Dermatol, Limoges, France

[15] Dijon Univ Hosp, Dept Dermatol, Dijon, France

[16] Besancon Univ Hosp, Dept Dermatol, EA3181, Besancon, France

[17] Ctr Hosp Univ Nantes, Dept Dermatol, Nantes, France

[18] Novartis Pharma France, Dept Med Oncol, Rueil Malmaison, France

[19] Hop St Andre, CHU Bordeaux, Dept Dermatol, Bordeaux, France

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1260P

引用

页数：2

共 50 条

[41] COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma
Hauschild, A.
Santinami, M.
Long, G. V.
Atkinson, V.
Mandala, M.
Sileni, V. Chiarion
Nyakas, M. S.
Dutriaux, C.
Haydon, A.
Robert, C.
Mortier, L.
Schachter, J.
Ji, R.
Zhang, P.
Mookerjee, B.
Legos, J.
Kefford, R.
Dummer, R.
Kirkwood, J.
ANNALS OF ONCOLOGY, 2017, 28
[42] Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
Schreuer, Max
Jansen, Yanina
Planken, Simon
Chevolet, Ines
Seremet, Teofila
Kruse, Vibeke
Neyns, Bart
LANCET ONCOLOGY, 2017, 18 (04): : 464 - 472
[43] Phase II randomized, placebo controlled study of sorafenib in combination with dacarbazine in subjects with unresectable Stage III or Stage IV melanoma
McDermott, D.
Sosman, J. A.
Hodi, F. S.
Gonzalez, R.
Linette, G.
Richards, J.
Jakub, J. K.
Beeram, M.
Patel, K.
Hersch, E.
EJC SUPPLEMENTS, 2007, 5 (04): : 396 - 396
[44] Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Grob, Jean Jacques
Amonkar, Mayur M.
Karaszewska, Boguslawa
Schachter, Jacob
Dummer, Reinhard
Mackiewicz, Andrzej
Stroyakovskiy, Daniil
Drucis, Kamil
Grange, Florent
Chiarion-Sileni, Vanna
Rutkowski, Piotr
Lichinitser, Mikhail
Levchenko, Evgeny
Wolter, Pascal
Hauschild, Axel
Long, Georgina V.
Nathan, Paul
Ribas, Antoni
Flaherty, Keith
Sun, Peng
Legos, Jeffrey J.
McDowell, Diane Opatt
Mookerjee, Bijoyesh
Schadendorf, Dirk
Robert, Caroline
LANCET ONCOLOGY, 2015, 16 (13): : 1389 - 1398
[45] Meta-analysis of randomized phase II-III trials evaluating triplet combinations of immunotherapy and targeted therapy for BRAF V600-mutant unresectable or metastatic melanoma.
Ferrucci, Pier Francesco
Gaeta, Aurora
Cocorocchio, Emilia
D'Ecclesiis, Oriana
Gandini, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) plus binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600-mutant melanoma
Schadendorf, D.
Dummer, R.
Flaherty, K. T.
Robert, C.
Arance Fernandez, A. M.
de Groot, J. W.
Garbe, C.
Gogas, H.
Gutzmer, R.
Krajsova, I.
Liszkay, G.
Loquai, C.
Mandala, M.
Yamazaki, N.
Guenzel, C. A.
Polli, A.
Thakur, M.
di Pietro, A.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2023, 34 : S670 - +
[47] COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) plus binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Haydon, A. M.
Schadendorf, D.
Dummer, R.
Flaherty, K. T.
Robert, C.
Arance Fernandez, A. M.
de Groot, J. W.
Garbe, C.
Gogas, H.
Gutzmer, R.
Krajsova, I.
Liszkay, G.
Loquai, C.
Mandala, M.
Yamazaki, N.
Guenzel, C. A.
Polli, A.
Thakur, M.
Di Pietro, A.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2023, 34 : S1707 - S1708
[48] Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma
Long, G. V.
Hauschild, A.
Santinami, M.
Atkinson, V. G.
Mandala, M.
Chiarion-Sileni, V.
Larkin, J.
Robert, C.
Schadendorf, D.
Dasgupta, K.
Shilkrut, M.
Garrett, J.
Brase, J. C.
Kefford, R.
Kirkwood, J. M.
Dummer, R.
ANNALS OF ONCOLOGY, 2018, 29
[49] Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.
Dummer, Reinhard
Long, Georgina V.
Tawbi, Hussein A.
Flaherty, Keith
Ascierto, Paolo Antonio
Nathan, Paul D.
Rutkowski, Piotr
Leonov, Oleg
Mandala, Mario
Lorigan, Paul
Ferrucci, Pier Francesco
Grob, Jean-Jacques
Meyer, Nicolas
Gogas, Helen
Stroyakovskiy, Daniil
Arance, Ana Maria
Pakhle, Neha
Waters, Sorcha
Ribas, Antoni
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) plus trametinib (T) or placebo (PBO).
Schadendorf, Dirk
Dummer, Reinhard
Hauschild, Axel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Chiarion-Sileni, Vanna
Larkin, James M. G.
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew Mark
Mortier, Laurent
Robert, Caroline
Schachter, Jacob
Ortmann, Christine-Elke
De Jong, Egbert
Gasal, Eduard
Kefford, Richard
Kirkwood, John M.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →